What's new? Log in Free sign up

Quoin Pharmaceuticals (QNRX)

Company Profile

Company profile

Ticker

QNRX

Exchange

Website

quoinpharma.com

CEO

Dr. Michael Myers Ph.D.

Incorporated

Location

Fiscal year end

Sector

Health Technology > Biotechnology

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Johnson & Johnson • Merck & Co. • Alabama Power • Mississippi Power • Teva Pharmaceutical Industries Limited • Abbott Laboratories • Eli Lilly and • Bristol-Myers Squibb • Viatris ...

Former names

Cellect Biomed Ltd., Cellect Biotechnology Ltd.

SEC CIK

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Plans of Reorganization

Material Contracts & Credit Agreements

Subsidiaries Lists

QNRX stock data

1M 3M 6M 1Y

Latest filings (excl ownership)

View all

Quoin Pharmaceuticals Announces Pricing of $6.8 Million Public Offering

Prospectus supplement with pricing info

Notice of effectiveness

IPO registration (amended)

18 Dec 24

IPO registration

Transcripts

View all

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Latest ownership filings

View all

Carter Denise P.

Carter Denise P.

Denise P. Carter

Anthony James Culverwell

Joseph Patrick Cooper

Financial summary

Financial statements Chart QNRX financial data

Quarter (USD)	Sep 24	Jun 24	Mar 24	Dec 23
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 23	Dec 22	Dec 21	Dec 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	3.12 mm	3.12 mm	3.12 mm	3.12 mm	3.12 mm	3.12 mm
Cash burn (monthly)	(no burn)	3.89 k	(no burn)	(no burn)	726.43 k	737.04 k
Cash used (since last report)	n/a	17.32 k	n/a	n/a	3.23 mm	3.28 mm
Cash remaining	n/a	3.10 mm	n/a	n/a	-118.09 k	-165.31 k
Runway (months of cash)	n/a	796.8	n/a	n/a	-0.2	-0.2

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q2 2024

QNRX institutional ownership history Ownership history

13F holders	Current	Prev Q	Change
Total holders	12	2	+500.0%
Opened positions	10	0	NEW
Closed positions	0	0
Increased positions	0	0
Reduced positions	0	0

13F shares	Current	Prev Q	Change
Total value	128.14 mm	465.00 k	+27457.6%
Total shares	1.27 bn	1.27 bn	+0.0%
Total puts	0.00	0.00
Total calls	0.00	0.00
Total put/call ratio	–	–	–

Largest owners	Shares	Value	Change
CVI Investments	1.27 bn	$0.00	0.0%
Lind Global Fund II	990.00 k	$465.00 k	0.0%
Altium Capital Management	103.13 k	$59.81 mm	NEW
Renaissance Technologies	34.20 k	$19.84 mm	NEW
Two Sigma Securities	23.46 k	$13.61 mm	NEW
Susquehanna International	15.43 k	$8.97 mm	NEW
Rhumbline Advisers	14.79 k	$8.59 mm	NEW
Two Sigma Investments	10.92 k	$6.34 mm	NEW
Resources Investment Advisors	10.40 k	$6.03 mm	NEW
UBS UBS	6.10 k	$3.54 mm	NEW

Largest transactions	Shares	Bought/sold	Change
Altium Capital Management	103.13 k	+103.13 k	NEW
Renaissance Technologies	34.20 k	+34.20 k	NEW
Two Sigma Securities	23.46 k	+23.46 k	NEW
Susquehanna International	15.43 k	+15.43 k	NEW
Rhumbline Advisers	14.79 k	+14.79 k	NEW
Two Sigma Investments	10.92 k	+10.92 k	NEW
Resources Investment Advisors	10.40 k	+10.40 k	NEW
UBS UBS	6.10 k	+6.10 k	NEW
BAC Bank of America	1.00 k	+1.00 k	NEW
JPM JPMorgan Chase & Co.	645.00	+645.00	NEW

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

QNRX insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
23 Dec 24	Gordon Dunn	Ordinary Shares	Buy	Acquire P	No	No	0.45	122,221	55.00 k	151,077
23 Dec 24	Gordon Dunn	Series G Warrants ADS	Buy	Acquire P	No	No	0.45	122,221	55.00 k	122,221
23 Dec 24	Gordon Dunn	Series F Warrants ADS	Buy	Acquire P	No	No	0.45	122,221	55.00 k	122,221
23 Dec 24	Denise P. Carter	Ordinary Shares	Buy	Acquire P	No	No	0.45	555,556	250.00 k	602,648
23 Dec 24	Denise P. Carter	Series G Warrants ADS	Buy	Acquire P	No	No	0.45	555,556	250.00 k	555,556
23 Dec 24	Denise P. Carter	Series F Warrants ADS	Buy	Acquire P	No	No	0.45	555,556	250.00 k	555,556
23 Dec 24	Anthony James Culverwell	Ordinary Shares	Buy	Acquire P	No	No	0.45	100,000	45.00 k	100,317
23 Dec 24	Anthony James Culverwell	Series G Warrants ADS	Buy	Acquire P	No	No	0.45	100,000	45.00 k	100,000
23 Dec 24	Anthony James Culverwell	Series F Warrants ADS	Buy	Acquire P	No	No	0.45	100,000	45.00 k	100,000
23 Dec 24	Michael Myers	Ordinary Shares	Buy	Acquire P	No	No	0.45	555,556	250.00 k	602,808

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

News

From Benzinga Pro

12 Health Care Stocks Moving In Friday's Pre-Market Session

12 Health Care Stocks Moving In Thursday's Pre-Market Session

Quoin Pharma Advances Netherton Syndrome Treatment, Partners with Skinvisible for FDA-Approved Topical Innovation

Skinvisible Pharmaceuticals, Inc. ("Skinvisible" or "the Company"), (OTCQB:SKVI), an innovative topical and transdermal pharmaceutical research and development company, with proprietary Invisicare® drug delivery

Quoin Pharmaceuticals Reports Interim Clinical Data From Ongoing Investigator Pediatric Netherton Syndrome Clinical Study

Quoin Pharmaceuticals Announces Additional Interim Data From Ongoing Open-Label Netherton Syndrome Clinical Study

Press releases

From Benzinga Pro

Quoin Pharmaceuticals Launches 'NETHERTON NOW' Campaign to Raise Awareness of Netherton Syndrome, a Rare Genetic Disease with No Approved Treatment or Cure

Multi-pronged media campaign to raise awareness about the disease and its impact on patients, family members and caregivers.Interactive, stand-alone NETHERTON NOW website launched.Quoin's QRX003 product is on track to

Quoin Pharmaceuticals Announces Further Clinical Evidence of QRX003 Effectiveness in Netherton Syndrome

Four Weeks After Discontinuation of Treatment with QRX003 Complete Reversal of Positive Clinical Improvements Across all Measured Endpoints ObservedData Supports QRX003 Mechanism of Action as a Competitive Broad Spectrum

Skinvisible Reports Licensee Success in Netherton Syndrome Clinical Studies

LAS VEGAS, NV / ACCESS Newswire / January 23, 2025 / Skinvisible Pharmaceuticals, Inc. ("Skinvisible" or "the Company"), (OTCQB:SKVI), an innovative topical and transdermal pharmaceutical research and

Quoin Pharmaceuticals Announces Further Positive Clinical Data from Ongoing Pediatric Netherton Syndrome Study

PRISM MarketView Spotlights Quoin Pharmaceuticals CEO Dr. Michael Myers as Specialty Pharma Shares News of Highly Positive Interim Data in Most Advanced, Comprehensive Netherton Syndrome Trials

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.